In Vivo Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures Against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Thigh Model [Experimental Therapeutics]

Herein we describe the in vivo efficacy of human-simulated WCK 5222 (cefepime-zidebactam) exposure against carbapenem-resistant Acinetobacter baumannii in a neutropenic murine thigh infection model. Five of six isolates examined expressed OXA-23 or OXA-24. WCK 5222, despite showing MICs 16 – 64 mg/L, produced remarkable in vivo activity; human-simulated exposure showed a decline in bacterial burden for all isolates [mean reduction -2.09 ± 1.01 log₁₀ CFU/thigh], while lack of activity was observed with cefepime and zidebactam monotherapies.

https://ift.tt/2qpGqB7